Bleeding in Patients Undergoing CABG (Coronary Artery Bypass Graft) During Dual Antiplatelet Therapy

N/ATerminatedNCT02030548

Medical University of Graz144 enrolled

Overview

The aim of the study is to evaluate surgery-related bleeding and mortality in patients needing acute coronary artery bypass grafting with or without valve replacement during dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker (Clopidogrel, Prasugrel, Ticagrelor)

Study Type

OBSERVATIONAL

Enrollment

144

Conditions

Acute Coronary Syndrome

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: consecutive patients undergoing acute CABG with or without valve replacement within 7 days after last intake of dual antiplatelet therapy Exclusion Criteria: concomitant oral anticoagulants dialysis surgery employing hypothermic cardiac arrest

Locations (1)

Dept. of Anesthesiology and Intensive Care Medicine

Graz, Styria, Austria

Outcomes

Primary Outcomes

calculated blood loss

Time frame: until postoperative day 5

Secondary Outcomes

mortality

Time frame: from index surgery until one year after index surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.